Slow Capital Inc. Purchases 600 Shares of BioNTech SE (NASDAQ:BNTX)

Slow Capital Inc. raised its position in BioNTech SE (NASDAQ:BNTX) by 1.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 51,680 shares of the company’s stock after acquiring an additional 600 shares during the period. BioNTech makes up approximately 0.9% of Slow Capital Inc.’s holdings, making the stock its 22nd biggest holding. Slow Capital Inc.’s holdings in BioNTech were worth $6,138,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. GAMMA Investing LLC grew its stake in BioNTech by 121.0% during the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after buying an additional 150 shares during the last quarter. Covestor Ltd grew its stake in shares of BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after acquiring an additional 133 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of BioNTech by 106.3% during the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after acquiring an additional 252 shares in the last quarter. Blue Trust Inc. increased its holdings in shares of BioNTech by 491.1% during the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after acquiring an additional 388 shares in the last quarter. Finally, Crewe Advisors LLC purchased a new position in shares of BioNTech in the 1st quarter valued at approximately $75,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on BNTX shares. Hsbc Global Res upgraded shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Jefferies Financial Group raised BioNTech from a “hold” rating to a “buy” rating and upped their target price for the company from $96.00 to $150.00 in a research report on Tuesday, September 17th. TD Cowen lowered their price target on BioNTech from $98.00 to $85.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. HSBC increased their price objective on BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a report on Monday, October 7th. Finally, HC Wainwright lifted their target price on BioNTech from $113.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, October 7th. Five equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $131.92.

BioNTech Price Performance

Shares of NASDAQ BNTX opened at $111.77 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. The stock has a market capitalization of $26.57 billion, a price-to-earnings ratio of 223.54 and a beta of 0.24. The firm’s 50 day simple moving average is $104.56 and its 200-day simple moving average is $94.18. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The firm had revenue of $128.70 million for the quarter, compared to analyst estimates of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The firm’s quarterly revenue was down 23.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.86) EPS. Analysts expect that BioNTech SE will post -3.04 EPS for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.